drugset / Trial / NCT02997761
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
Phase 2
Completed
19 enrolled
University of California, Davis
National Cancer Institute (NCI) · collabPharmacyclics LLC. · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread. Giving ibrutinib and blinatumomab may work better in treating patients with relapsed or refractory B acute lymphoblastic leukemia.
Timeline
- Start
- 2017-06-27
- Primary completion
- 2025-07-17
- Completion
- 2025-07-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | — | Intravenous |
| Subject | Ibrutinib | Small molecule | — | Oral |